Insights from ASCO 2023.

Authors :: Hartkopf A
Janni W
Banys-Paluchowski M
Bidard FC
Thomssen C
Source :: Breast care (Basel, Switzerland) [Breast Care (Basel)] 2023 Dec; Vol. 18 (6), pp. 493-496. Date of Electronic Publication: 2023 Sep 26.
Publication Year :: 2023
Abstract: Competing Interests: W. Janni: no conflict of interest to declare. M. Banys-Paluchowski: Honoraria for lectures and participation in advisory boards: Roche, Novartis, Pfizer, pfm, Eli Lilly, onkowissen, Seagen, AstraZeneca, Eisai, Amgen, Samsung, Canon, MSD, GSK, Daiichi Sankyo, Gilead, Sirius Medical, Syantra, Resitu, Pierre Fabre, Exact Sciences. Study support from: Endomag, Mammotome, Merit Medical, Sirius Medical, Gilead, Hologic, Exact Sciences. Travel reimbursement: Eli Lilly, Exact Sciences, Pierre Fabre, Pfizer, Daiichi Sankyo, Roche. F.C. Bidard: consulting or advisory board: Pfizer; AstraZeneca; Lilly; Novartis; Menarini; Sanofi; GSK; Rain Oncology; Caris Life Sciences; GE Healthcare; Exact Sciences; Gilead. Speaker’s bureau: Pfizer; Novartis; AstraZeneca; Roche; Lilly; Rain Oncology; Daiichi Sankyo; Menarini-Stemline. Research funding: Novartis; Pfizer; Menarini Silicon Biosystems; ProLynx; Merck KGaA; GE Healthcare. C. Thomssen: no conflict of interest to declare.